Rhythm Pharma

Commercial-stage biopharma specializing in rare neuroendocrine diseases, with IMCIVREE (setmelanotide) in Phase 3 for obesity syndromes; backed by licensing deals with LG Chem, Ipsen, Camurus, and joint research with Axovia.

Headquarters: United States (USA)

Rhythm Pharma Logo
Company Profile
  • Employees: 283
  • HQ: Boston
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
RYTM Rhythm Pharma
Cap: 6.7B
EQUITY NMS USD US76243J1051 Active
📈
Home Login